Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Rating of “Hold” by Analysts

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have been assigned a consensus rating of “Hold” from the six analysts that are currently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $9.60.

Several equities analysts have weighed in on VRCA shares. TD Cowen cut their price target on Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating for the company in a report on Monday, October 21st. Needham & Company LLC restated a “hold” rating on shares of Verrica Pharmaceuticals in a report on Tuesday, November 5th. HC Wainwright cut Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, November 6th. Brookline Capital Management restated a “hold” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, October 2nd. Finally, Royal Bank of Canada cut Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price target for the company from $11.00 to $2.00 in a report on Tuesday, November 5th.

Verrica Pharmaceuticals Stock Performance

NASDAQ:VRCA opened at $0.76 on Tuesday. The company has a current ratio of 1.34, a quick ratio of 1.22 and a debt-to-equity ratio of 29.58. Verrica Pharmaceuticals has a 12-month low of $0.70 and a 12-month high of $11.41. The stock has a 50-day moving average price of $1.18 and a 200 day moving average price of $3.83. The stock has a market capitalization of $34.70 million, a P/E ratio of -0.42 and a beta of 1.40.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its earnings results on Monday, November 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.12). Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. The business had revenue of ($1.78) million for the quarter, compared to analysts’ expectations of $7.53 million. Equities research analysts forecast that Verrica Pharmaceuticals will post -1.42 EPS for the current fiscal year.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of Verrica Pharmaceuticals by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,268,710 shares of the company’s stock worth $7,511,000 after acquiring an additional 7,609 shares during the last quarter. State Street Corp lifted its stake in shares of Verrica Pharmaceuticals by 13.5% during the 3rd quarter. State Street Corp now owns 512,821 shares of the company’s stock worth $744,000 after acquiring an additional 61,041 shares during the last quarter. Simplify Asset Management Inc. bought a new stake in shares of Verrica Pharmaceuticals during the 2nd quarter worth approximately $2,041,000. XTX Topco Ltd bought a new stake in shares of Verrica Pharmaceuticals during the 3rd quarter worth approximately $335,000. Finally, Jane Street Group LLC raised its position in Verrica Pharmaceuticals by 106.5% during the 3rd quarter. Jane Street Group LLC now owns 69,872 shares of the company’s stock valued at $101,000 after purchasing an additional 36,028 shares in the last quarter. Hedge funds and other institutional investors own 42.45% of the company’s stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.